2021
November 22, 2021
DNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual Meeting
September 14, 2021
DNAtrix Announces the Appointment of David Liebowitz, M.D., Ph.D., as Chief Medical Officer
June 9, 2021
DNAtrix to Present at the Raymond James Human Health Innovations Conference
February 18, 2021
DNAtrix Appoints Industry Veteran Herb Cross to its Board of Directors
2020
January 13, 2020
DNAtrix Appoints Jeff Knapp as Chief Executive Officer and to Board of Directors
2019
2018
November 26, 2018
DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial
November 15, 2018
DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma
November 13, 2018
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
October 24, 2018
First Clinical Study Initiated for DNX-2440, DNAtrix's Next Generation Armed Oncolytic Virus
July 2, 2018
Treatment of Pediatric Brain Tumor, DIPG, with Oncolytic Adenovirus DNX-2401 to be Presented at the 2018 International Symposium for Pediatric Neuro-Oncology
May 8, 2018
Successful Delivery of DNAtrix’s Oncolytic Virus DNX-2401 to Pediatric Brain Tumors
April 12, 2018
Effectiveness of DNAtrix Oncolytic Virus DNX-2440 Armed with OX40L to be Presented at the 2018 American Association for Cancer Research Annual Meeting